We are live on ! Find out more

CNTB

Connect Biopharma Holdings

CNTB

Market cap $147M

2.33 USD

-0.12

4.9%

At close Updated Aug 26, 4:00 PM EDT

Pre-market

After hours

2.34

+0.01

0.43%

1 day

-4.9%

5 days

-6.05%

1 month

10.95%

3 months

-2.92%

6 months

-7.54%

Year to date

-7.54%

1 year

34.68%

5 years

-88.57%

10 years

-87.4%

About: Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Employees: 64

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and six months ended June 30, 2026, and provided a business update. “During the second quarter, we achieved important milestones with the completion of enrollment in both our Phase 2 Seabreeze STAT asthma and chronic obstructive pulmonary disease (COPD) studies.

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which have the potential to show a benefit of rademikibart for acute exacerbations. CNTB raised net proceeds of $18.6M in Q1'26 with a private placement, with cash of $46M at the end of that quarter.

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, as an adjunct to standard of care for acute exacerbations in participants with asthma and type 2 inflammation. “Completion of enrollment in our Seabreeze STAT Asthma study marks another significant step in our mission to deliver the first biologic to treat patients suffering from an acute exacerbation of asthma,” said Barry Quart, Pharm.D.

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026

Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.

Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent in China Phase 3 trials, with commercialization led by Simcere and low-double-digit royalties to CNTB. CNTB is targeting the emergency asthma and COPD settings in the US, a market with no approved biologics, and expects pivotal Phase 2 data in mid-2026.

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size. “Based on the DMC's review of interim efficacy results from our ongoing Seabreeze STAT acute asthma and COPD studies, enrollment will continue as planned with no change in sample size,” said Barry Quart, Pharm.D.

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 – SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and twelve months ended December 31, 2025, and provided a business update. “2025 was an eventful year for our lead drug candidate, rademikibart, with the initiation of our Phase 2 Seabreeze STAT studies in acute asthma and chronic obstructive pulmonary disease (COPD),” said Barry Quart, Pharm.D.

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

See News Rankings

Price charts implemented using Lightweight Charts™